Y0000401
Pimobendan for system suitability
European Pharmacopoeia (EP) Reference Standard
동의어(들):
Pimobendan, 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-3(2H)-pyridazinone
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C19H18N4O2
CAS Number:
Molecular Weight:
334.37
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24
추천 제품
![4-Chloro-N-[2-(4-hydroxyphenyl)ethyl]benzamide AldrichCPR](/deepweb/assets/sigmaaldrich/product/structures/139/662/1ce3ff3b-f928-4434-88d9-f4981db0fc47/640/1ce3ff3b-f928-4434-88d9-f4981db0fc47.png)
Grade
pharmaceutical primary standard
API family
pimobendan
제조업체/상표
EDQM
응용 분야
pharmaceutical (small molecule)
형식
neat
저장 온도
2-8°C
SMILES string
CC(C(C1=CC=C(NC(C2=CC=C(OC)C=C2)=N3)C3=C1)=NN4)CC4=O
InChI
1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)
InChI key
GLBJJMFZWDBELO-UHFFFAOYSA-N
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Pimobendan for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
신호어
Danger
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 3 Oral
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
[Calcium mobilizers and calcium sensitizers].
Masashi Arai
Nihon rinsho. Japanese journal of clinical medicine, 69 Suppl 9, 417-422 (2012-06-26)
M W S Martin et al.
The Journal of small animal practice, 51(8), 428-436 (2010-07-31)
To review the association between clinical signs and diagnostic findings and the survival time of dogs with dilated cardiomyopathy (DCM), and any influence of treatment prescribed. A retrospective observational study of 367 dogs with DCM. Survival times until death or
Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.
Adrian Boswood et al.
The Veterinary record, 168(8), 222-222 (2011-04-16)
Domenico Caivano et al.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 14(3), 431-444 (2012-08-14)
Interventional cardiac procedures are traditionally performed using fluoroscopy, or, more recently, transesophageal echocardiography (TEE). Neither modality is widely available to practicing cardiologists worldwide. We examined whether balloon valvuloplasty of pulmonic stenosis (PS) and transarterial occlusion of patent ductus arteriosus (PDA)
Andrea C Lantis et al.
American journal of veterinary research, 72(12), 1646-1651 (2011-12-01)
To evaluate the effect of administration of the labeled dosage of pimobendan to dogs with furosemide-induced activation of the renin-angiotensin-aldosterone system (RAAS). 12 healthy hound-type dogs. Dogs were allocated into 2 groups (6 dogs/group). One group received furosemide (2 mg/kg
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.